Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 16/20 | 0.53 |
| ▸ | ESR1 | P03372 | 14/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466520 | 0.84 | ESR1 (0.51) | ESR2ESR1ALDH1A1LMNAMAPT | |
| SCHEMBL2399693 | 0.80 | ESR2 (0.53) | ESR2ESR1 | |
| SCHEMBL14170020 | 0.79 | ESR2 (0.51) | ESR2ESR1 | |
| SCHEMBL12266842 | 0.79 | ESR2 (0.50) | ESR2ESR1 | |
| SCHEMBL4473647 | 0.78 | ESR2 (0.52) | ESR2ESR1 | |
| SCHEMBL14169838 | 0.77 | ESR2 (0.73) | ESR2ESR1 | |
| SCHEMBL14172927 | 0.76 | ESR2 (0.48) | ESR2ESR1 | |
| SCHEMBL2399680 | 0.76 | ESR2 (0.47) | ESR2ESR1 | |
| SCHEMBL14172910 | 0.75 | ESR2 (0.53) | ESR2ESR1MAPT | |
| SCHEMBL12266846 | 0.74 | ESR2 (0.66) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531564-B2 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1982713-A2 | Substituted benzoxazoles and analogues as estrogenic agents | Wyeth (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080255057-A1 | PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS | WYETH (US) | 2008-10-16 | — | — | US | disclosed |
| US-20070167503-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2007-07-19 | — | — | US | disclosed |
| EP-1781628-A2 | PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS | Wyeth a Corporation of the State of Delaware (US) | 2007-05-09 | — | — | EP | disclosed |
| US-7148247-B2 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2006-12-12 | — | — | US | disclosed |
| US-7129258-B2 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2006-10-31 | — | — | US | disclosed |
| WO-2006026316-A2 | PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS | WYETH (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060046968-A1 | Prodrug substituted benzoxazoles as estrogenic agents | WYETH (US) | 2006-03-02 | — | — | US | disclosed |
| US-20050239851-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050080117-A1 | Substituted benzoxazoles as estrogenic agents | WYETH (US) | 2005-04-14 | — | — | US | disclosed |
| US-6794403-B2 | FOR TREATING OR INHIBITING INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, ULCERATIVE PROCTITIS OR COLITIS PROSTATIC HYPERTROPHY, UTERINE LEIOMYOMAS, BREAST CANCER, ENDOMETRIAL CANCER, CARDIOVASCULAR DISEASE, ALZHEIMER'S DISEASE | WYETH | 2004-09-21 | — | — | US | disclosed |
| EP-1451165-A1 | SUBSTITUTED BENZOXAZOLES AND ANALOGUES AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | WYETH | 2003-10-23 | — | — | US | disclosed |
| WO-2003050095-A1 | SUBSTITUTED BENZOXAZOLES AND ANALOGUES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255057-A1 | PRODRUG SUBSTITUTED BENZOXAZOLES AS ESTROGENIC AGENTS | ESR1, CYP19A1, ESR2 | ESR2 3/4885ESR1 1/4885ALDH1A1 818/4885 |
| US-20050239851-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | ESR2 2/4885ESR1 1/4885ALDH1A1 1038/4885 |
| US-20050080117-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | ESR2 2/4885ESR1 1/4885ALDH1A1 1038/4885 |
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | ESR2 2/4885ESR1 1/4885ALDH1A1 875/4885 |
| US-20070167503-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | ESR2 2/4885ESR1 1/4885ALDH1A1 1038/4885 |
| US-20060046968-A1 | Prodrug substituted benzoxazoles as estrogenic agents | ESR1, CYP19A1, ESR2 | ESR2 3/4885ESR1 1/4885ALDH1A1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.